Vermillion Wealth Management’s Guardant Health GH Stock Holding History

Vermillion Wealth Management’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-9	Closed	-$831	–	1898
2026 Q1	$831	Buy	+9	New	+$904	﹤0.01%	865

Other funds holding GH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vermillion Wealth Management's GH Position: Q2 2026 in Review

Vermillion Wealth Management sold out of Guardant Health (GH) in Q2 2026, closing a stake of 9 shares — an estimated $831 sold.

Vermillion Wealth Management first reported a position in GH in Q1 2026 and held it in 1 quarter. The position peaked at $831 in Q1 2026. 597 funds tracked by Wall St. Rank hold GH as of Q2 2026.

Vermillion Wealth Management reported no remaining Guardant Health position as of Q2 2026 after selling out during the quarter.
Vermillion Wealth Management sold 9 Guardant Health shares in Q2 2026, an estimated $831.
Vermillion Wealth Management first reported a position in Guardant Health in Q1 2026 and held it in 1 quarter.
Vermillion Wealth Management's Guardant Health position peaked at $831 in Q1 2026.
597 funds tracked by Wall St. Rank held Guardant Health as of Q2 2026.

Based on Vermillion Wealth Management's 13F filing for Q2 2026, filed 16 Jul 2026.